Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Terns Pharmaceuticals (TERN) Shares Issued (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Shares Issued readings, the most recent being $705.6 million for Q4 2025.

  • Quarterly Shares Issued rose 159018.92% to $705.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $705.7 million through Dec 2025, up 113181.86% year-over-year, with the annual reading at $36.8 million for FY2025, 5814.13% up from the prior year.
  • Shares Issued hit $705.6 million in Q4 2025 for Terns Pharmaceuticals, up from -$106000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $705.6 million in Q4 2025 and bottomed at -$136.3 million in Q2 2021.
  • Average Shares Issued over 5 years is $56.3 million, with a median of $53500.0 recorded in 2023.
  • The largest annual shift saw Shares Issued plummeted 2706.25% in 2021 before it skyrocketed 159018.92% in 2025.
  • Terns Pharmaceuticals' Shares Issued stood at -$898000.0 in 2021, then skyrocketed by 9132.85% to $81.1 million in 2022, then crashed by 99.96% to $33000.0 in 2023, then tumbled by 1445.45% to -$444000.0 in 2024, then skyrocketed by 159018.92% to $705.6 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Shares Issued are $705.6 million (Q4 2025), -$106000.0 (Q3 2025), and $178000.0 (Q2 2025).